Article
Discordancy in BRAF mutations among primary and metastatic melanoma lesions: clinical implications for targeted therapy.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc - 1 Apr 2015
Bradish Joshua R, Richey Justin D, Post Kristin M, Meehan Kari, Sen Joyashree D, Malek Amanda J, Katona Terrence M, Warren Simon, Logan Theodore F, Fecher Leslie A, Cheng Liang
Abstract excerpt
Systemic targeted molecular therapy, in the form of a selective BRAF inhibitor with or without a MEK inhibitor, is a standard treatment for patients with BRAF V600 mutation-positive melanoma with unresectable stage III and IV disease. Patients with BRAF mutation-negative primary tumors may manifest BRAF mutation-positive metastatic disease. It is unclear whether all metastatic lesions carry the same BRAF mutation...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.